Honeybear Biosciences Wins “Most Promising Award” at 2025 NBRP Demo Day, Pioneers Taiwan’s First ARC Drug to Lead Cancer Innovation Read more
Honeybear Biosciences Shines at the 2025 Taiwan Biotech Forum CoNectar® Technology Wows the Audience and Perfectly Crystalizes the Brand Spirit of Honeybear Read more
CEO Dr. Chuang, Simon, Shih-Hsien, Attends World ADC Asia Presented Latest ARC Research Results and Received Highly Regard Read more
Dr. Sun, Wei-Ting Delivers Invited Lecture at TMU, Offering In-Depth Analysis of ADC Development Trends Honeybear’s Unique CoNectar® Platform Draws Lots of Attention Read more
HoneyBear Biosciences and A*STAR Team Successfully Complete Two Licensing Agreements in Singapore Read more
Dr. Chuang, Simon, Shih-Hsien, CEO of HoneyBear Biosciences, invited to give a speech at ADC Congress Asia Read more
Special Interview on Startup 101—"Next-Generation Cancer Drug Platform, Becoming a Lifeline for Patients: Interview with HoneyBear Biosciences" Read more
“Process For Preparing Glycoprotein-Drug Conjugates”awarded with Silver award of the 8th National invention and creation award granted by Ministry of Economic Affairs. Read more
Simon Shih-Hsien Chuang, CEO of Honeybear Biosciences invited to give a speech in 2023 BioAsia Read more
“First ADC drug with dual anti-cancer effects worldwide” press conference on March 13th, 2023 Read more
